Biocatalytic N-Halogenation Enabled by Vanadium-Dependent Haloperoxidases

Kyle F. Biegasiewicz,Manik Sharma,Zoe E. Patton,Carlie R. Shoemaker,John Bacsa
DOI: https://doi.org/10.26434/chemrxiv-2024-1jpzc
2024-06-18
Abstract:Nitrogen-containing compounds are valuable synthetic intermediates and targets in nearly every chemical industry. While methods for nitrogen-carbon and nitrogen-heteroatom bond formation have primarily relied on nucleophilic nitrogen atom reactivity, molecules containing nitrogen-halogen bonds allow for reactivity through electrophilic or radical mechanisms at the nitrogen center. Despite the growing synthetic utility of nitrogen-halogen-containing compounds, selective catalytic strategies for their synthesis are largely underexplored. We recently discovered that the vanadium-dependent haloperoxidase (VHPO) class of enzymes are a suitable biocatalyst platform for nitrogen-halogen bond formation. Herein, we show that VHPOs perform selective halogenation of a range of substituted benzamidine hydrochlorides to produce the corresponding N’-halobenzimidamides. This biocatalytic platform is applied to the synthesis of 1,2,4-oxadiazoles from the corresponding N-acylbenzamidines in high yield and with excellent chemoselectivity. Finally, the synthetic applicability of this biotechnology is demonstrated in an extension to nitrogen-nitrogen bond formation and the chemoenzymatic synthesis of the Duchenne muscular dystrophy treatment, ataluren.
Chemistry
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to develop an efficient and selective catalytic method for the formation of nitrogen - halogen bonds (N - X), especially to achieve this goal by means of biocatalysis. Specifically, the researchers explored the application of vanadium - dependent haloperoxidases (VHPOs) as biocatalysts in nitrogen halogenation reactions to synthesize compounds containing nitrogen - halogen bonds, such as N' - halophenylamidines and 1,2,4 - oxadiazoles. These compounds have important application values in many fields such as medicinal chemistry and materials science, but traditional synthesis methods often have problems such as harsh conditions and poor selectivity, which limit their application scope. By using VHPOs, the researchers aim to provide a milder, more efficient and environmentally - friendly synthesis route. The paper also shows the application of this biocatalytic technology in the synthesis of Ataluren, a drug for the treatment of Duchenne muscular dystrophy, further demonstrating its potential in actual drug synthesis.